DM
SYRE icon

Deerfield Management’s Spyre Therapeutics SYRE Stock Holding History

Deerfield Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-710,626
Closed -$23.3M – 147
2025
Q4 		$23.3M Buy
710,626
+96,961
+16% +$2.53M 0.3% 58
2025
Q3 		$10.3M Hold
613,665
– – 0.16% 70
2025
Q2 		$9.19M Buy
613,665
+163,665
+36% +$2.42M 0.17% 67
2025
Q1 		$7.26M Hold
450,000
– – 0.14% 75
2024
Q4 		$10.5M Buy
+450,000
New +$13.2M 0.2% 63
2020
Q3 		– Sell
-33,000
Closed -$7.63M – 114
2020
Q2 		$7.63M Buy
+33,000
New +$6.28M 0.22% 81
2019
Q4 		– Sell
-20,002
Closed -$3.85M – 93
2019
Q3 		$3.85M Hold
20,002
– – 0.16% 77
2019
Q2 		$3.42M Hold
20,002
– – 0.12% 87
2019
Q1 		$4.03M Buy
+20,002
New +$4.17M 0.15% 76

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Deerfield Management's SYRE Position: Q1 2026 in Review

Deerfield Management sold out of Spyre Therapeutics (SYRE) in Q1 2026, closing a stake of 710,626 shares — an estimated $23.3M sold.

Deerfield Management first reported a position in SYRE in Q1 2019 and held it in 9 quarters. The position peaked at $23.3M in Q4 2025. 198 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Deerfield Management reported no remaining Spyre Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Deerfield Management sold 710,626 Spyre Therapeutics shares in Q1 2026, an estimated $23.3M.
  • Deerfield Management first reported a position in Spyre Therapeutics in Q1 2019 and held it in 9 quarters.
  • Deerfield Management's Spyre Therapeutics position peaked at $23.3M in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Deerfield Management's 13F filing for Q1 2026, filed 15 May 2026.